Crossmark

Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study

Crossref DOI link: https://doi.org/10.1016/j.jaad.2023.10.026

Published Print: 2024-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Veverka, Karen A.

Thng, Steven T.G.

Silverberg, Jonathan I.

Armstrong, April W.

Menezes, Josemund

Kaoukhov, Alexandre

Blauvelt, Andrew https://orcid.org/0000-0003-0084-3131
License Information

Text and Data Mining valid from 2024-03-01

Version of Record valid from 2023-10-19
More Information

This article is maintained by: Elsevier

Article Title: Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study

Journal Title: Journal of the American Academy of Dermatology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.jaad.2023.10.026

Content Type: article

Copyright: © 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.

Document is current

Any future updates will be listed below